湖南华纳大药厂股份有限公司 关于完成工商变更登记并换发营业执照的公告

Core Viewpoint - The company has completed significant corporate governance changes, including capital restructuring and board adjustments, which are aimed at enhancing operational efficiency and compliance with regulatory requirements [1]. Group 1: Corporate Governance Changes - The company held its fourth board meeting and fourth supervisory board meeting on December 10, 2025, and a second extraordinary shareholders' meeting on December 26, 2025, to approve various governance changes [1]. - The approved changes include alterations to registered capital, cancellation of the supervisory board, adjustments to the number of board members, and amendments to the company's articles of association [1]. Group 2: Registration and Compliance - The company has completed the necessary business registration changes and has received a new business license from the Changsha Market Supervision Administration [1]. - The updated registered capital is set at 13.132 million yuan [1]. - The company operates as a joint-stock company with a focus on pharmaceutical research and manufacturing, including a wide range of products from chemical drugs to traditional Chinese medicine [1].